The second paragraph for those who think this post is not relevant due to its title:
> I believe this change could be significant. Recently, Section 5 was used to litigate against pharmacy benefit managers. It’s in the antitrust case against Amazon, another case against Corteva/Syngenta over exclusive dealing in seeds and chemicals, and it was the authority used to ban non-compete agreements. These cases, as well as every consent decree ever reached under Section 5, are now at risk.
> I believe this change could be significant. Recently, Section 5 was used to litigate against pharmacy benefit managers. It’s in the antitrust case against Amazon, another case against Corteva/Syngenta over exclusive dealing in seeds and chemicals, and it was the authority used to ban non-compete agreements. These cases, as well as every consent decree ever reached under Section 5, are now at risk.